TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00144417
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : August 3, 2011
Global Alliance for TB Drug Development
Information provided by:
Centers for Disease Control and Prevention

Brief Summary:
This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.

Condition or disease Intervention/treatment Phase
Tuberculosis Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) Drug: isoniazid Phase 2

Detailed Description:

The primary objective of this Phase 2 clinical trial is to compare the safety and antimicrobial activity of a moxifloxacin-containing regimen (moxifloxacin, rifampin, pyrazinamide, ethambutol [MRZE]) in which moxifloxacin has been substituted for isoniazid, to the standard control regimen (isoniazid, rifampin, pyrazinamide, ethambutol [HRZE]) in the first two months of treatment of sputum smear-positive pulmonary tuberculosis. The assessment of antimicrobial activity will be sputum culture-conversion. Higher rates of sputum culture conversion after 2 months of treatment with a moxifloxacin-containing regimen would support Phase 3 clinical trials of moxifloxacin in treatment regimens of less than the current 6 month standard regimens.

Rationale - Current treatment of smear positive pulmonary tuberculosis requires a minimum of 6 months, a treatment duration that is challenging for patients and tuberculosis control programs. Therefore, a high priority in tuberculosis research is the identification of agents that can shorten treatment. Several fluoroquinolone antibiotics have potent activity against Mycobacterium tuberculosis (M. tuberculosis) in preclinical testing. Of the currently available fluoroquinolones, moxifloxacin has excellent activity in vitro and in animal models of tuberculosis, a favorable pharmacokinetic profile (serum half-life of 10-12 hours), lack of problematic drug-drug interactions, no need for dosage adjustment for renal and hepatic insufficiency, and an excellent safety profile. In addition, in the murine model of tuberculosis, the substitution of moxifloxacin for isoniazid resulted in significant reductions in the time to culture conversion and the time to sterilization when compared to the standard combination rifampin, isoniazid and pyrazinamide. However, moxifloxacin has not been fully evaluated in humans for tuberculosis treatment. There is a need to assess not only the anti-tuberculosis activity of moxifloxacin-containing regimens, but also the safety of more prolonged therapy with moxifloxacin.

Two-month culture conversion rates are a well-accepted surrogate marker for the sterilizing activity of anti-tuberculosis drugs. Rifampin and pyrazinamide, the key drugs in current 6-month regimens, markedly increase 2-month culture-conversion rates. Therefore, this study will use 2-month culture conversion rate as the measure of antimicrobial activity of moxifloxacin.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 433 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment
Study Start Date : February 2006
Actual Primary Completion Date : June 2007
Actual Study Completion Date : December 2007

Arm Intervention/treatment
Active Comparator: HRZE
isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
Drug: isoniazid
isoniazid, oral, 300 mg, daily, 8 weeks
Experimental: MRZE
moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)
Moxifloxacin 400mg daily, 8 weeks

Primary Outcome Measures :
  1. • To compare the culture-conversion rate at the end of the intensive phase of therapy of the moxifloxacin regimen vs. that of the isoniazid regimen [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. To compare the safety and tolerability of the moxifloxacin regimen to that of the isoniazid regimen [ Time Frame: 8 weeks ]
  2. To determine the time to culture-conversion of the moxifloxacin regimen and the isoniazid regimen using data from 2-, 4-, 6-, and 8-week cultures [ Time Frame: 8 weeks ]
  3. To compare the proportion of patients with any Grade 3 or 4 adverse reactions [ Time Frame: 8 weeks ]
  4. To compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients [ Time Frame: 8 weeks ]
  5. To compare the rates of treatment failure of the moxifloxacin regimen and the isoniazid regimen [ Time Frame: 6 months ]
  6. To determine whether there is delayed toxicity attributable to moxifloxacin (toxicity that becomes evident after the 8 weeks of moxifloxacin therapy) [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated or induced sputum. Patients whose sputum cultures do not grow M. tuberculosis and those having an M. tuberculosis isolate resistant to (one or more) isoniazid, rifampin, fluoroquinolones, will be discontinued from the study, but followed for 14 days to detect late toxicities from study therapy. Patients having extra-pulmonary manifestations of tuberculosis, in addition to smear-positive pulmonary disease, are eligible for enrollment. Sputum must be expectorated or induced; smear results from respiratory secretions obtained by bronchoalveolar lavage or bronchial wash may not be used for assessment of study eligibility.
  • Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 6 months prior to enrollment. HIV testing does not need to be repeated if there is written documentation of a positive test (positive ELISA and Western Blot or a plasma HIV-RNA level greater than 5000 copies/ml) at any time in the past.
  • 7 (seven) or fewer days of multidrug therapy for tuberculosis disease in the 6 months preceding enrollment.
  • 7 (seven) or fewer days of fluoroquinolone therapy in the 3 months preceding enrollment.
  • Age > 18 years
  • Karnofsky score of at least 60 (requires occasional assistance but is able to care for most of his/her needs; see Appendix B).
  • Signed informed consent
  • Women with child-bearing potential must agree to practice an adequate (barrier) method of birth control or to abstain from heterosexual intercourse during study therapy.
  • Laboratory parameters done at, or <14 days prior to, screening:
  • Serum amino aspartate transferase (AST) activity ≤ 3 times the upper limit of normal
  • Serum total bilirubin level ≤ 2.5 times the upper limit of normal
  • Serum creatinine level ≤ 2 times the upper limit of normal
  • Complete blood count with hemoglobin level of at least 7.0 g/dL
  • Complete blood count with platelet count of at least 50,000/mm3
  • Serum potassium > 3.5 meq/L
  • Negative pregnancy test (women of childbearing potential)

Exclusion Criteria:

  • Breast-feeding
  • Known intolerance to any of the study drugs
  • Known allergy to any fluoroquinolone antibiotic
  • Concomitant disorders or conditions for which moxifloxacin (MXF), isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These include severe hepatic damage, acute liver disease of any cause, and acute uncontrolled gouty arthritis.
  • Current or planned therapy during the intensive phase of therapy using drugs having unacceptable interactions with rifampin (rifabutin can be substituted for rifampin during the continuation phase of therapy).
  • Current or planned antiretroviral therapy during the intensive phase of therapy.
  • History of prolonged QT syndrome or current or planned therapy with quinidine, procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine during the intensive phase of therapy.
  • Pulmonary silicosis
  • Central nervous system TB

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00144417

  Hide Study Locations
United States, Arkansas
Veterans Administration Medical Center of Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
University of Southern California Medical Center
Los Angeles, California, United States, 90033
University of California at San Diego
San Diego, California, United States, 92103
University of California, San Francincisco
San Francisco, California, United States, 94110
United States, Colorado
Denver Public Health Department
Denver, Colorado, United States, 80204
United States, District of Columbia
Washington DC Veterans Administration Medical Center
Washington DC, District of Columbia, United States, 20422
United States, Georgia
Emory University School of Medicine
Atlanta, Georgia, United States, 30303
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Hines Veterans Administration Medical Center
Hines, Illinois, United States, 60141
United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Boston University Medical Center
Boston, Massachusetts, United States, 02118
United States, New Jersey
New Jersey School of Medicine
Newark, New Jersey, United States, 07103
United States, New York
Columbia University
New York, New York, United States, 10032
Harlem Hospital, Columbia University
New York, New York, United States, 10037
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Tennessee
Veterans Administration Tennessee Valley Health Care System
Nashville, Tennessee, United States, 37232
United States, Texas
University of North Texas Health Science Center
Fort Worth, Texas, United States, 76104
Houston Veterans Administration Medical Center
Houston, Texas, United States, 77030
Audie L Murphy Memorial Veterans Administration Medical Center
San Antonio, Texas, United States, 78284
United States, Washington
Seattle-King County Health Department
Seattle, Washington, United States, 98104
Hopital Universitario Clementino Fraga Filho
Rio de Janeiro, Brazil, 2194.590
Canada, Manitoba
University of Manitoba
Winnepeg, Manitoba, Canada, R3A 1R8
Canada, Quebec
Montreal Chest Institute
Montreal, Quebec, Canada, H2X 2P4
South Africa
Nelson R. Mandela School of Medicine
Durban, KwaZulu Natal, South Africa
Agencia de Salut Publica
Barcelona, Spain, 08023
Makerere University Medical School
Kampala, Uganda
Sponsors and Collaborators
Centers for Disease Control and Prevention
Global Alliance for TB Drug Development
Study Chair: Richard E Chaisson, MD Johns Hopkins University
Principal Investigator: Susan E Dorman, MD Johns Hopkins University
Principal Investigator: John L Johnson, MD Case Western Reserve University

Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Stefan Goldberg, CHSRB/DTBE/NCHHSTP/CDC Identifier: NCT00144417     History of Changes
Other Study ID Numbers: CDC-NCHSTP-4448
First Posted: September 5, 2005    Key Record Dates
Last Update Posted: August 3, 2011
Last Verified: June 2011

Keywords provided by Centers for Disease Control and Prevention:

Additional relevant MeSH terms:
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors
Antibiotics, Antitubercular
Antitubercular Agents
Leprostatic Agents
Cytochrome P-450 CYP2B6 Inducers